The present invention generally relates to the field of disease management. More particularly, and without limitations, the invention relates to systems and methods for disease management by providing treatment recommendations and information based on relevant data collected about a patient.
Generally speaking, disease management refers to a wide range of activities that may affect a patient's health status. These activities include programs to improve a patient's compliance with their treatment regimen, and helping the patient adjust their regimen according to evidence-based treatment guidelines. The goal of these programs is to attempt to maintain or improve the patient's health status and quality of life, and to reduce the total costs of health care.
One approach is to identify and provide a variety of appropriate services to patients that are suitable for a certain program. Examples of such services include periodic phone calls to a patient to monitor the status of the patient, personalized goal-oriented feedback on the patient's self care, access to nurse call centers, and educational materials. Some of these programs attempt to modify services based on data obtained from the patient's self reports and administrative claims. These programs attempt to help patients identify regimens, manage their symptoms, self-monitor their conditions, and comply with their treatment. The drawbacks of this type of approach include the enormous resources necessary to provide these human-based services, and the lack of timely, appropriate, and accurate patient data to provide appropriate services. For example, a single case manager can only assist a limited number of patients. As a result, such a case manager may, for example, be able to contact a patient only once a month and may be forced to rely on out-dated data for the patient.
An alternative approach for disease management is to use a system that provides corrective action to a patient based on limited information provided by the patient. For example, a diabetes patient can provide their current glucose value using an electronic patient-operated apparatus, and the system can recommend a corrective action to the patient based on the application of formulas well known in the art. A corrective action can be either administration of an extra insulin dose or consumption of carbohydrates. A drawback of this approach is that it fails to provide customized disease management for each individual patient. Similarly, the formulas that can be applied for any patient part of the general population do not take into account the complete dynamics of a particulars patient's disease and the corrective actions advised to a patient are limited. As a result, a patient is denied the optimal treatment recommendations that can only be targeted for a particular patient. Finally, the success of the system is wholly dependent on a proactive and conscientious patient.
In view of the foregoing, there is a need for an improved solution for disease management. In particular, there is a need for systems and methods for effective disease management that can develop recommendations for a patient based on the particular patient's data.
The present invention provides methods, computer-readable media, and systems for providing disease management. This is achieved by providing treatment recommendations targeted for a particular patient based on the patient's data.
In one exemplary embodiment, a system is provided including, for example, an input device for receiving patient data; a transmitter for transmitting the received patient data from the input device; and a disease management server. The disease management server may include a receiver for receiving the transmitted patient data, a processor for developing a treatment recommendation, and an output device for outputting the treatment recommendation. The processor may develop treatment recommendations by executing a basic model of the physiological system of the patient to generate a modified model for the patient based on the patient data, performing a statistical analysis of the patient data to detect data excursions of the parameter values, using the modified model to determine factors causing the data excursions, and using the model to develop a treatment recommendation to ameliorate negative effects of the disease. The patient data may include but is not limited to the following parameters: patient carbohydrate intake, patient medication doses, blood glucose level, activity of the patient, and the corresponding time and optional context for the data.
The processor in the disease management server of the exemplary system may generate a plurality of treatment recommendations, including, for example, recommendations for dosing and timing of medication, and for patient dietary behavior. Executing the model comprises applying an algorithm to the patient data in a current state in conjunction with auxiliary patient data including, for example, patient blood lipid level, blood pressure, age, gender, height and weight, and race. The processor may be further configured to develop recommendations for collection of the patient data to improve the model, wherein the collection recommendations comprise recommendations for timing of blood glucose measurement. The processor may be further configured to perform statistical analysis employing a statistical design of experiments methodology and multivariate analyses to identify the factors causing the data excursions.
In another embodiment, the treatment recommendations may be developed at predetermined intervals, which may be determined based on a most-recent patient data collection time. The treatment recommendations may include a recommended time and dose of medication, including recommended combinations of available medications. The treatment recommendations may also include a recommended time and amount of carbohydrate intake.
In another alternate embodiment, the input device may be a patient-interactive interface operated by the patient. The system may include a portable device configured to operate the patient-interactive interface and the transmitter, wherein the transmitter transmits signals over a wireless communication to the disease management server. The system may also include a physician interface operable to receive information about the patient from the disease management server.
In another alternate embodiment, the patient data may be calibrated at a plurality of reading points to provide more information on pharmacokinetic/pharmacodynamic interactions of the patient.
In another alternate embodiment, generating the modified model may include utilizing equations that simulate interaction of primary factors effecting rate of change of the blood glucose of the patient, wherein the primary factors are calculated based on the patient data. The primary factors may include rate of digestion of the patient carbohydrate intake, cellular uptake of blood glucose by the patient, and impact of glucose inventory in liver, skeletal muscle, and fat tissues of the patient. The equation for the cellular uptake is a function of the blood glucose level, level of insulin acting as a catalyst, resistance factors, and digestive-activated hormones, and wherein the level of insulin is calculated based on the patient medication doses, patient pancreatic production, and insulin kinetics.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.
The accompanying drawings, which are incorporated in and constitute a part of this disclosure, illustrate embodiments and aspects of the present invention. In the drawings:
The following detailed description refers to the accompanying drawings. Wherever possible, the same reference numbers are used in the drawings and the following description to refer to the same or similar parts. While several exemplary embodiments and features of the invention are described herein, modifications, adaptations and other implementations are possible, without departing from the spirit and scope of the invention. For example, substitutions, additions, or modifications may be made to the components illustrated in the drawings, and the exemplary methods described herein may be modified by substituting, reordering, or adding steps to the disclosed methods. Accordingly, the following detailed description does not limit the invention. Instead, the proper scope of the invention is defined by the appended claims.
Input device 110 and the transmitter 120 may be part of a single computer system. Alternatively, the transmitter may be on an intermediary computer system between the input device 110 and the disease management server 130. The transmitter 120 may serve as the intermediary for communication between the input device 110 and the disease management server. The components 110, 120, 130 may communicate with each over a communication medium 125. The communication medium may be any desired type of communication channel, including (but not limited to) the public switched telephone network (VSTN), cellular channel, other wireless channel, internal computer bus, intranet, Internet, etc.
The input device 110 may be used to collect variety of patient data in a variety of ways. The input device 110 may be connected to one or more biometric measurement devices to collect biometric data. The biometric measurement devices may be implanted in the patient, connected to the patient, and/or completely external. A biometric measurement device may be part of or connected to the input device 110, or it may be a stand-alone device. A stand-alone biometric measurement device may communicate wirelessly with the input device 110, Examples of biometric measurement devices include, but are not limited to, scales, external blood pressure monitors, cardiac data sensors, implantable blood glucose sensors for continuous sensing, external blood glucose monitors, etc.
The input device 110 may also receive information from devices for administering medication. For example, the input device 110 may be connected to an insulin-delivery device. The input device 110 may receive information detailing the insulin doses a patient has taken from the insulin-delivery device and the times of dose administration.
The input device 110 may also receive information from other ancillary devices to collect a variety of information about the patient's behavior and status. For example, the input device 110 may be connected to a pedometer worn by the patient or exercise equipment used by the patient to track the physical activity of the patient. The input device 110 may be connected to a GPS system to track the movement and location of the patient. The input device may also be connected to a device that keeps track of a patient's dietary behavior.
The input device 110 may also receive information by having the patient enter particular information. The disease management server 130 may send request for particular information to be entered by the patient using the input device 110. The input device 110 may prompt the user to enter the particular information. The request sent by the disease management server 130 may be in the form of surveys designed to collect particular information. The surveys may be targeted to collect information about a patient's dietary behavior (e.g., carbohydrate intake, portion control), self-monitoring of blood glucose, medication doses, physical activity, psychological status, alcohol intake, smoking activity, and any other information that might effect the patient's well being. The input device 110 may prompt the patient to enter information by displaying the survey and receiving the patient's responses to the questions posed in the survey. The scripts may also be designed to educate the patient or to promote positive behavior/behavior modification by the patient.
The transmitter 120 may send the patient data collected by the input device 110 to the disease management server 130 immediately after the data is entered into the input device 110 by the patient.
As shown in
The processor 132 may generate a modified model for the patient based on the patient data the disease management server 130 receives through the receiver 131. The modified model may be used to estimate impact of a change in the patient's regimen (e.g., medication, food intake, physical activity) on the physiological system of the patient. The processor may generate a modified model for the patient by executing a basic model. A basic model models a physiological system of a patient based on established knowledge of disease dynamics and factors. The patient data is used to generate the modified model for a particular patient. The modified model can provide guidance to improve the patient's regimen and to gain a better understanding of how a particular patient is being affected by a disease dynamic. The use of patient data over an extended period of time allows the modification and improvements of the modified model as more data is collected for a particular patient. The modified model may also be used even when limited/incomplete patient data is received.
After the generation of a modified model, the processor 132 may perform a statistical analysis of patient data to detect data excursions. A data excursion is an event in which a value of a parameter (e.g., blood glucose level) is outside the normal/expected range for the parameter. The processor 132 may use the modified model it generated to determine the factors causing the data excursions and the effects of such data excursions. The modified model may then be used to develop a plurality of treatment recommendations to ameliorate negative effects of the disease. The output device 133 within the disease management server 130 may output information based on the treatment recommendations to the patient, a device relate to the patient, or a third party.
At step 301, the input device 110 may receive data collected by one or more biometric measurement devices. The input device 110 may receive the data collected by one or more biometric measurement devices every time a measurement occurs by the biometric measurement device, at a certain predetermined interval, or when the input device is prompted to collect the biometric measurement data. Alternatively, as discussed above, at step 301, the biometric measurement data may be entered by the patient into the input device 110.
At step 302, the input device may prompt the user to enter specific information pertaining to factors that can effect the well being of the patient. The patient may be prompted to enter such information by being asked a series of questions. The patient may receive reminders through the input device to enter certain type of information at a certain time. Step 302 may repeat several times to collect different types of data from the patient at steps 301, 303, 304, 305.
At step 303, the input device 110 may receive information about the patient's dietary behavior. This information may be simply entered by the patient on a regular basis using the input device. The patient may use a remote workstation to enter the information and have it transferred to the input device. The information may be entered in response to the prompt(s) at step 302. The information may be received from a device that can track a patient's dietary behavior. An example of such a device is a food/drink caloric intake calculator. The calculator may be implemented, for example, on a cell phone, and a patient may enter information regarding his/her dietary behavior into the cell phone. Alternatively, the calculator may be part of the input device. The information may also be received by the input device 110 from a restaurant where the patient eats. Another example is a camera-based food calculator. The input device 110 may be able to receive pictures of food eaten by the patient. Image recognition techniques may later be used to identify the food consumed by the patient, and determine the carbohydrate intake of the patient for example.
At step 304, the input device 110 may receive information about what medications the patient is taking, at what doses, and at what times. The patient may simply enter the information to be received by the input device independently, or the patient may enter the information in response to a prompt at step 302. The input device 110 may also be connected to other devices, and may receive information regarding the patient's medication intake from the other devices.
At step 305, the input device 110 may receive any other pertinent information from the patient that may assist successful disease management. This information may be received directly from the patient, a health care provider, a monitoring device, a third party, etc, A person can be prompted by the input device 110 to enter the information. Examples of information that may be collected may relate to the patient's exercise, smoking, alcohol intake, etc.
The input device 110 may also receive information from the patient at steps 301, 303, 304, and 305 regarding patients attitude towards modifying behavior that affects the respective data received at each step.
At step 402, the disease management server 130 uses the patient data to generate a modified model of the patient's physiological system. The modified model may be used to estimate the impact of a change of a certain factor (data) on the patient (other data). The modified model represents the effects of a change in different data on the particular patient's physiological system, and in turn how the physiological system of the patient effects the data. The modified model may be a previously generated modified model updated based on new patient data. The model is generated by executing a basic model based on the patient data (402). The basic model represents the minimal assumptions and parameters of a person's physiological system and the correlation of certain factors. How the factors interact and correlate is different for different patients. The patient data is used to adjust the basic model and generate a modified model for a particular patient. The more patient data is collected over time, the more accurate the modified model is for the particular patient. In addition, the collection of data from multiple patients may be used to improve the basic model.
At step 403, the disease management server 130 performs a statistical analysis to detect data excursions in the patient data. A data excursion may be indicated when certain data collected at a certain time is outside the normal range that can be expected for that data for the particular patient. For example, a data excursion may be a blood glucose measurement that is outside the normal blood glucose range for the particular patient.
At step 404, the disease management server 130 uses the modified model generated at step 402 to determine the factors causing the data excursions detected at step 403. For example, the disease management server 130 may determine if a change in amount of timing of medication or food intake of the patient caused the data excursion of blood glucose measurement.
At step 405, the disease management server 130 may develop treatment recommendations to ameliorate negative effects of the patient's disease. The disease management server 130 may use the modified model to determine the treatment recommendations which are optimal for the patient. For example, if a data excursion caused a negative effect on the patient, a treatment recommendation may be developed to prevent such a data excursion in the future. Examples of treatment recommendations may include adjusting food or medication intake, adjusting how and what data is collected, advising the patient to modify certain behaviors, providing educational materials to the patient, alerting the patient's health care provider, etc.
At step 406, the output device 133 of disease management server 130 may output the treatment recommendations developed at step 405. The treatment recommendations are transmitted to the appropriate party or device. For example, a treatment recommendation to increase the patient's insulin dose can be transmitted directly to the insulin-delivery device (pump). If, for example, the treatment recommendation is to collect certain additional data about the patient to provide optimal treatment recommendations in the future, a script can be transmitted to the patient through the input device 110 to collect the additional data at certain times.
After determining the carbohydrate intake of the patient, an impact of the carbohydrate intake (carbs) on concentration of the blood glucose may be modeled (502). This may be modeled based on the following equation for instantaneous blood glucose concentration:
wherein [BG] may be blood glucose (BG) concentration, [carbs] may be represented as a first order kinetics function of time (t), β may be for example about 5 BG units/carbohydrate unit, and incretins are the digestive-activated hormones of the patient.
The impact of insulin on transfer of blood glucose into patient's cells (504) is accounted for in the modified model. Insulin is accounted for as a catalyst, not as a compound that forms with blood glucose. The instantaneous rate decrease of blood glucose concentration from instantaneous insulin concentration in blood may be modeled based on the following equation: wherein
[insulin] may be the instantaneous insulin concentration in blood, a includes resistance impact of diabetes and is about 0.3 if rate is −50 BG units/insulin unit above BG of 140, and α(t) includes diurnal variations. Alternatively, α(t) may be approximated without any time dependence, using the 24 hour mean.
Finally, it is necessary to account for the impact of the glucose inventory (IG) on the blood glucose (BG) (506), where the glucose inventory absorbs blood glucose on storage and release blood glucose on retrieval (mass action kinetics). This may be modeled based on the following equation:
where
wherein τ is the threshold; if resistant insulin is greater then the threshold, then blood glucose decreases by going into liver and fat as glucose storage (IG) and is not released through the liver. And wherein γ relates concentration of glucose to changes in IG. The IG functionality may be modeled by other similar forms at the conceptual level since the phenomenological description is incomplete.
The total change in blood glucose over a time interval (508) may be modeled based on the sum of the three factors 502, 504, 506 described above. The complete basic model may be based on the following equation (509):
where the storage or release of blood glucose as mediated by resistant insulin may be expressed in the following equation:
wherein W is the switching rate (i.e., the rate that IG switches from intake mode to output mode of BG). Errors may account for any additional or unknown factors besides the primary factors (507). Statistical methods may be used to estimate model parameters and their expected variations for a patient.
The model can then be used to determine factors causing the data excursions 404. The relative contributions of the primary factors may vary over the 24 hour day, especially adjacent to meals and fasting events. For example, the fasting segments of the BG profile between meals would see lithe impact from the carbohydrates (502), and, if in addition, insulin levels are near their norm's as defined by its storage threshold, then insulin (504) becomes the dominant effect. Hence, this allows an estimation of the a parameter and the insulin profile of the patient based on the model. The dosing profile is known (503), and comparison with the estimated profile provides information on pancreatic activity. Under these conditions, one can also test if a changes among different fasting events. The testing can be accomplished through a treatment recommendation. The model provide a guide for timely regimen optimization for the particular patient. The optimization is based on a minimal-assumption model (MAM) that fits the major features in the data patterns of the patient. The MAM for BG data patterns may be expressed, for example, as follows: BG=MAM(t, injections, orals, digestion, diurnals, activity, liver processes, immune reaction, beta islets)+error.
Given α, one can estimate inventory parameters from the segments of the model capturing fasting events at non-normal levels of insulin. With these two sources established, one can now estimate the impact of carbohydrates during meals, since carbohydrates kinetics are known. Similarly, the MAM may be used to determine the effect on the patient's BG of changing other factors (ex. medications). A key feature of MAM is that it can model answers to “what if” questions for each individual patient given any scenario of lifestyle and treatment regimen/conditions over any interval of time both retrospectively and prospectively.
The foregoing description has been presented for purposes of illustration. It is not exhaustive and does not limit the invention to the precise forms or embodiments disclosed. Modifications and adaptations of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the disclosed embodiments of the invention. For example, the described implementations include software, but systems and methods consistent with the present invention may be implemented as a combination of hardware and software or in hardware alone. Examples of hardware include computing or processing systems, including personal computers, servers, laptops, mainframes, micro-processors and the like, Additionally, although aspects of the invention are described for being stored in memory, one skilled in the art will appreciate that these aspects can also be stored on other types of computer-readable media, such as secondary storage devices, for example, hard disks, floppy disks, or CD-ROM, the Internet or other propagation medium, or other forms of RAM or ROM.
Computer programs based on the written description and methods of this invention are within the skill of an experienced developer. The various programs or program modules can be created using any of the techniques known to one skilled in the art or can be designed in connection with existing software. For example, program sections or program modules can be designed in or by means of Java, C++, HTML, XML, or HTML with included Java applets. One or more of such software sections or modules can be integrated into a computer system or existing e-mail or browser software.
Moreover, while illustrative embodiments of the invention have been described herein, the scope of the invention includes any and all embodiments having equivalent elements, modifications, omissions, combinations (e.g., of aspects across various embodiments), adaptations and/or alterations as would be appreciated by those in the art based on the present disclosure. The limitations in the claims are to be interpreted broadly based on the language employed in the claims and not limited to examples described in the present specification or during the prosecution of the application, which examples are to be construed as non-exclusive. Further, the steps of the disclosed methods may be modified in any manner, including by reordering steps and/or inserting or deleting steps, without departing from the principles of the invention. It is intended, therefore, that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims and their full scope of equivalents.
This application is a continuation of U.S. patent application Ser. No. 15/670,551, filed on Aug. 7, 2017, which is a continuation of U.S. patent application Ser. No. 12/071,486, filed on Feb. 21, 2008, now U.S. Pat. No. 9,754,077, which claims the benefit of priority to U.S. Provisional Patent Application No. 60/902,490, filed on Feb. 22, 2007, the entireties of each of which are incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
3810102 | Parks, III et al. | May 1974 | A |
4173971 | Karz | Nov 1979 | A |
4428733 | Kumar-Misir | Jan 1984 | A |
4439242 | Hadden | Mar 1984 | A |
4712562 | Ohayon et al. | Dec 1987 | A |
4731726 | Allen, III | Mar 1988 | A |
4803625 | Fu et al. | Feb 1989 | A |
4835372 | Gombrich et al. | May 1989 | A |
4838275 | Lee | Jun 1989 | A |
4960118 | Pennock | Oct 1990 | A |
5019974 | Beckers | May 1991 | A |
5036462 | Kaufman et al. | Jul 1991 | A |
5036852 | Leishman | Aug 1991 | A |
5077476 | Rosenthal | Dec 1991 | A |
5307263 | Brown | Apr 1994 | A |
5339921 | Fujimoto | Sep 1994 | A |
5348008 | Bornn et al. | Sep 1994 | A |
5377258 | Bro | Dec 1994 | A |
5390238 | Kirk et al. | Feb 1995 | A |
5437278 | Wilk | Aug 1995 | A |
5437634 | Amano | Aug 1995 | A |
5465082 | Chaco | Nov 1995 | A |
5544661 | Davis et al. | Aug 1996 | A |
5569212 | Brown | Oct 1996 | A |
5596994 | Bro | Jan 1997 | A |
5601435 | Quy | Feb 1997 | A |
5626144 | Tacklind et al. | May 1997 | A |
5628209 | Brown | May 1997 | A |
5692906 | Corder | Dec 1997 | A |
5704922 | Brown | Jan 1998 | A |
5720733 | Brown | Feb 1998 | A |
5722418 | Brown | Mar 1998 | A |
5730654 | Brown | Mar 1998 | A |
5772586 | Heinonen et al. | Jun 1998 | A |
5782814 | Brown et al. | Jul 1998 | A |
5792117 | Brown | Aug 1998 | A |
5794219 | Brown | Aug 1998 | A |
5822715 | Worthington et al. | Oct 1998 | A |
5828943 | Brown | Oct 1998 | A |
5832448 | Brown | Nov 1998 | A |
5879163 | Brown et al. | Mar 1999 | A |
5887133 | Brown et al. | Mar 1999 | A |
5897493 | Brown | Apr 1999 | A |
5899855 | Brown | May 1999 | A |
5902234 | Webb | May 1999 | A |
5913310 | Brown | Jun 1999 | A |
5918603 | Brown | Jul 1999 | A |
5933136 | Brown | Aug 1999 | A |
5940801 | Brown | Aug 1999 | A |
5941829 | Saltzstein | Aug 1999 | A |
5951300 | Brown | Sep 1999 | A |
5956501 | Brown | Sep 1999 | A |
5960403 | Brown | Sep 1999 | A |
5967975 | Ridgeway | Oct 1999 | A |
5977059 | Khoo | Nov 1999 | A |
5985559 | Brown | Nov 1999 | A |
5997476 | Brown | Dec 1999 | A |
6023686 | Brown | Feb 2000 | A |
6024699 | Surwit et al. | Feb 2000 | A |
6032119 | Brown et al. | Feb 2000 | A |
6068615 | Brown et al. | May 2000 | A |
6101478 | Brown | Aug 2000 | A |
6110148 | Brown et al. | Aug 2000 | A |
6113578 | Brown | Sep 2000 | A |
6144837 | Quy | Nov 2000 | A |
6151586 | Brown | Nov 2000 | A |
6161095 | Brown | Dec 2000 | A |
6167362 | Brown et al. | Dec 2000 | A |
6167386 | Brown | Dec 2000 | A |
6168563 | Brown | Jan 2001 | B1 |
6186145 | Brown | Feb 2001 | B1 |
6196970 | Brown | Mar 2001 | B1 |
6210272 | Brown | Apr 2001 | B1 |
6231519 | Blants et al. | May 2001 | B1 |
6233539 | Brown | May 2001 | B1 |
6234964 | Iliff et al. | May 2001 | B1 |
6240393 | Brown | May 2001 | B1 |
6246992 | Brown | Jun 2001 | B1 |
6248065 | Brown | Jun 2001 | B1 |
6260022 | Brown | Jul 2001 | B1 |
6270455 | Brown | Aug 2001 | B1 |
6302844 | Walker et al. | Oct 2001 | B1 |
6330426 | Brown et al. | Dec 2001 | B2 |
6334778 | Brown | Jan 2002 | B1 |
6352523 | Brown et al. | Mar 2002 | B1 |
6368273 | Brown | Apr 2002 | B1 |
6375469 | Brown | Apr 2002 | B1 |
6375614 | Braun et al. | Apr 2002 | B1 |
6379301 | Worthington et al. | Apr 2002 | B1 |
6381577 | Brown | Apr 2002 | B1 |
6402691 | Peddicord et al. | Jun 2002 | B1 |
6409660 | Sjogvist et al. | Jun 2002 | B1 |
6416471 | Kumar et al. | Jul 2002 | B1 |
6418346 | Nelson et al. | Jul 2002 | B1 |
6454705 | Cosentino et al. | Sep 2002 | B1 |
6482156 | Iliff et al. | Nov 2002 | B2 |
6565509 | Say et al. | May 2003 | B1 |
6579231 | Phipps | Jun 2003 | B1 |
6510010 | Sjogvist et al. | Aug 2003 | B1 |
6602191 | Quy | Aug 2003 | B2 |
6610012 | Mault et al. | Aug 2003 | B2 |
6645142 | Braig et al. | Nov 2003 | B2 |
6669631 | Norris et al. | Dec 2003 | B2 |
6675030 | Ciurczak et al. | Jan 2004 | B2 |
6694177 | Eggers et al. | Feb 2004 | B2 |
6699188 | Wessel | Mar 2004 | B2 |
6723045 | Cosentino et al. | Apr 2004 | B2 |
6723046 | Lichtenstein et al. | Apr 2004 | B2 |
6783492 | Dominguez et al. | Aug 2004 | B2 |
6804558 | Haller et al. | Oct 2004 | B2 |
6820057 | Loch et al. | Nov 2004 | B1 |
6840904 | Goldberg | Jan 2005 | B2 |
6849045 | Iliff | Feb 2005 | B2 |
6885544 | Austin | Mar 2005 | B2 |
6875174 | Braun et al. | Apr 2005 | B2 |
6891936 | Kai et al. | May 2005 | B2 |
6893396 | Schulze et al. | May 2005 | B2 |
6920360 | Lee et al. | Jul 2005 | B2 |
6936007 | Quy | Aug 2005 | B2 |
6955646 | Christ et al. | Oct 2005 | B2 |
6968375 | Brown et al. | Nov 2005 | B1 |
6976958 | Quy | Dec 2005 | B2 |
6985762 | Brashears et al. | Jan 2006 | B2 |
7077806 | Ackermann et al. | Jul 2006 | B2 |
7104955 | Bardy | Sep 2006 | B2 |
7130396 | Rogers et al. | Oct 2006 | B2 |
7156808 | Quy | Jan 2007 | B2 |
7156809 | Quy | Jan 2007 | B2 |
7167818 | Brown | Jan 2007 | B2 |
7188151 | Kumar et al. | Mar 2007 | B2 |
7223235 | Brown | May 2007 | B2 |
7223236 | Brown | May 2007 | B2 |
7252636 | Brown | Aug 2007 | B2 |
7258666 | Brown | Aug 2007 | B2 |
7260480 | Brown et al. | Aug 2007 | B1 |
7264591 | Brown | Sep 2007 | B2 |
7277867 | Brown et al. | Oct 2007 | B1 |
7297109 | Brown | Nov 2007 | B2 |
7305348 | Brown | Dec 2007 | B1 |
7310668 | Brown | Dec 2007 | B2 |
7320030 | Brown | Jan 2008 | B2 |
7321920 | Washburn | Jan 2008 | B2 |
7392167 | Brown | Jan 2008 | B2 |
7340503 | Washburn | Mar 2008 | B2 |
7353258 | Washburn | Apr 2008 | B2 |
7399276 | Brown et al. | Jul 2008 | B1 |
20010011224 | Brown | Aug 2001 | A1 |
20010016310 | Brown et al. | Aug 2001 | A1 |
20010039373 | Cunningham et al. | Nov 2001 | A1 |
20010047252 | Brown | Nov 2001 | A1 |
20010049096 | Brown | Dec 2001 | A1 |
20020016719 | Nemeth et al. | Feb 2002 | A1 |
20020019748 | Brown | Feb 2002 | A1 |
20020026223 | Riff et al. | Feb 2002 | A1 |
20020039373 | Ishimaru | Apr 2002 | A1 |
20020052539 | Haller et al. | May 2002 | A1 |
20020111541 | Bibl et al. | Aug 2002 | A1 |
20020120310 | Linden et al. | Aug 2002 | A1 |
20020128866 | Goetzke | Sep 2002 | A1 |
20020133377 | Brown | Sep 2002 | A1 |
20030000088 | Korth et al. | Jan 2003 | A1 |
20030036683 | Kehr et al. | Feb 2003 | A1 |
20030072424 | Evans et al. | Apr 2003 | A1 |
20030088290 | Spinelli et al. | May 2003 | A1 |
20030163351 | Brown et al. | Aug 2003 | A1 |
20030166994 | Ooshima et al. | Sep 2003 | A1 |
20030208113 | Mault | Nov 2003 | A1 |
20030212579 | Brown et al. | Nov 2003 | A1 |
20030229514 | Brown | Dec 2003 | A2 |
20040019259 | Brown et al. | Jan 2004 | A1 |
20040044272 | Moerman et al. | Mar 2004 | A1 |
20040054263 | Moerman et al. | Mar 2004 | A1 |
20040102683 | Khanuja et al. | May 2004 | A1 |
20040102685 | Cosentino et al. | May 2004 | A1 |
20040106855 | Brown | Jun 2004 | A1 |
20040107116 | Brown | Jun 2004 | A1 |
20040117207 | Brown | Jun 2004 | A1 |
20040117208 | Brown | Jun 2004 | A1 |
20040117209 | Brown | Jun 2004 | A1 |
20040117210 | Brown | Jun 2004 | A1 |
20040122297 | Stahmann et al. | Jun 2004 | A1 |
20040133080 | Mazar et al. | Jul 2004 | A1 |
20040176666 | Chait | Sep 2004 | A1 |
20040215492 | Choi | Oct 2004 | A1 |
20040236189 | Hawthorne et al. | Nov 2004 | A1 |
20040236199 | Hawthorne et al. | Nov 2004 | A1 |
20040249250 | Mcgee et al. | Dec 2004 | A1 |
20050003470 | Nelson et al. | Jan 2005 | A1 |
20050010087 | Banet et al. | Jan 2005 | A1 |
20050059895 | Brown | Mar 2005 | A1 |
20050060194 | Brown | Mar 2005 | A1 |
20050065815 | Mazar et al. | Mar 2005 | A1 |
20050075542 | Goldreich | Apr 2005 | A1 |
20050080322 | Korman | Apr 2005 | A1 |
20050080652 | Brown | Apr 2005 | A1 |
20050086083 | Brown | Apr 2005 | A1 |
20050113655 | Hull | May 2005 | A1 |
20050197553 | Cooper | Sep 2005 | A1 |
20050216199 | Banet | Sep 2005 | A1 |
20050228883 | Brown | Oct 2005 | A1 |
20050234307 | Heinonen et al. | Oct 2005 | A1 |
20050235060 | Brown | Oct 2005 | A1 |
20050240111 | Chung | Oct 2005 | A1 |
20050273509 | Brown | Dec 2005 | A1 |
20050283385 | Hunkeler | Dec 2005 | A1 |
20060004611 | Brown | Jan 2006 | A1 |
20060009684 | Kim | Jan 2006 | A1 |
20060009697 | Banet et al. | Jan 2006 | A1 |
20060009705 | Brown | Jan 2006 | A1 |
20060009706 | Brown | Jan 2006 | A1 |
20060010014 | Brown | Jan 2006 | A1 |
20060017563 | Rosenfeld et al. | Jan 2006 | A1 |
20060022834 | Rosenfeld et al. | Feb 2006 | A1 |
20060025657 | Rosenfeld et al. | Feb 2006 | A1 |
20060036134 | Tarassenko et al. | Feb 2006 | A1 |
20060036619 | Fuerst | Feb 2006 | A1 |
20060074338 | Greenwald et al. | Apr 2006 | A1 |
20060080152 | Brown | Apr 2006 | A1 |
20060089542 | Sands | Apr 2006 | A1 |
20060089969 | Brown | Apr 2006 | A1 |
20060100910 | Brown | May 2006 | A1 |
20060129432 | Choi et al. | Jun 2006 | A1 |
20060142648 | Banet et al. | Jun 2006 | A1 |
20060155582 | Brown | Jul 2006 | A1 |
20060167345 | Vespasiani | Jul 2006 | A1 |
20060167346 | Sarel | Jul 2006 | A1 |
20060173260 | Gaoni et al. | Aug 2006 | A1 |
20060173715 | Wang | Aug 2006 | A1 |
20060178914 | Brown | Aug 2006 | A1 |
20060189853 | Brown | Aug 2006 | A1 |
20060212316 | Jackson et al. | Sep 2006 | A1 |
20060234202 | Brown | Oct 2006 | A1 |
20060235722 | Brown | Oct 2006 | A1 |
20060241975 | Brown | Oct 2006 | A1 |
20060247951 | Brown | Nov 2006 | A1 |
20060252089 | Brown | Nov 2006 | A1 |
20060253296 | Liisberg et al. | Nov 2006 | A1 |
20060253303 | Brown | Nov 2006 | A1 |
20060253574 | Brown | Nov 2006 | A1 |
20060253576 | Brown | Nov 2006 | A1 |
20060259201 | Brown | Nov 2006 | A1 |
20060259332 | Brown | Nov 2006 | A1 |
20060271214 | Brown | Nov 2006 | A1 |
20060271404 | Brown | Nov 2006 | A1 |
20060285660 | Brown | Dec 2006 | A1 |
20060285736 | Brown | Dec 2006 | A1 |
20060287883 | Turgiss | Dec 2006 | A1 |
20060287889 | Brown | Dec 2006 | A1 |
20060287931 | Brown | Dec 2006 | A1 |
20060293571 | Bao et al. | Dec 2006 | A1 |
20060293607 | Alt et al. | Dec 2006 | A1 |
20060294233 | Brown | Dec 2006 | A1 |
20070010719 | Huster et al. | Jan 2007 | A1 |
20070011320 | Brown | Jan 2007 | A1 |
20070016445 | Brown | Jan 2007 | A1 |
20070016446 | Brown | Jan 2007 | A1 |
20070016447 | Brown | Jan 2007 | A1 |
20070018448 | Brown | Jan 2007 | A1 |
20070021984 | Brown | Jan 2007 | A1 |
20070032997 | Brown | Feb 2007 | A1 |
20070048691 | Brown | Mar 2007 | A1 |
20070055486 | Brown | Mar 2007 | A1 |
20070060796 | Kim | Mar 2007 | A1 |
20070061167 | Brown | Mar 2007 | A1 |
20070067251 | Brown | Mar 2007 | A1 |
20070068539 | Hall et al. | Mar 2007 | A1 |
20070076681 | Brown | Apr 2007 | A1 |
20070094049 | Brown | Apr 2007 | A1 |
20070094353 | Brown | Apr 2007 | A1 |
20070100665 | Brown | May 2007 | A1 |
20070100932 | Brown | May 2007 | A1 |
20070100934 | Brown | May 2007 | A1 |
20070118348 | Brown | May 2007 | A1 |
20070118403 | Brown | May 2007 | A1 |
20070118404 | Brown | May 2007 | A1 |
20070118588 | Brown | May 2007 | A1 |
20070118589 | Brown | May 2007 | A1 |
20070124179 | Brown | May 2007 | A1 |
20070124466 | Brown | May 2007 | A1 |
20070135688 | Brown | Jun 2007 | A1 |
20070156457 | Brown | Jul 2007 | A1 |
20070156893 | Brown | Jul 2007 | A1 |
20070168226 | Brown | Jul 2007 | A1 |
20070168242 | Brown | Jul 2007 | A1 |
20070168504 | Brown | Jul 2007 | A1 |
20070179352 | Randlov et al. | Aug 2007 | A1 |
20070212671 | Brown | Sep 2007 | A1 |
20070213603 | Brown | Sep 2007 | A1 |
20070213604 | Brown | Sep 2007 | A1 |
20070213605 | Brown | Sep 2007 | A1 |
20070213608 | Brown | Sep 2007 | A1 |
20070287895 | Brown | Dec 2007 | A1 |
Number | Date | Country |
---|---|---|
WO 9963462 | Dec 1999 | WO |
Entry |
---|
Montani et al., “Protocol-based Reasoning in Diabetic Patient Management,” International Journal of Medical Informatics, Elsevier Scientific Publishers, Shannon, IR, vol. 53, No. 1, Jan. 1, 1999, pp. 61-77. |
Lehmann et al., “AIDA2: : A Mk. II Automated Insulin Dosage Advisor,” Journal of Biomedical Engineering, Butterworth, Guildford, GB, vol. 15, No. 3, May 1, 1993, pp. 201-211. |
Deutsch T et al., “Utopia: A Consultation System for Visit-by-Visit Diabetes Management,” Medical Informatica, Taylor and Francis, Basingstoke, GB, vol. 21, No. 4, Oct. 1, 1996, pp. 345-358. |
Steil G. M. et al., “Modeling Insulin Action for Development of a Closed-Loop Artificial Pancreas,” Diabetes Technology and Therapeutics, Mary Ann Liebert, Larchmont, NY, vol. 7, No. 1, Feb. 1, 2005, pp. 94-109. |
Boutayeb A. et al., “A critical reviewk of Mathematical Models and Data Used in Diabetology,” Biomedical Engineering Online, Biomed Central Ltd., London, England, vol. 5, No. 1, Jun. 19, 2006. |
Rune V. Overgaard et al., “Mathematical Beta Cell Model for Insulin Secretion Following IVGIT and OGTT,” Annals of Biomedical Engineering, Kluwer Academic Publishers-Plenum Publishers, NE, vol. 34, No. 8, Jul. 13, 2006. |
Minor J. M. et al., “Analysis of Clinical Data Using Neural Nets,” Journal of Biopharmaceutical Statistics, Mar. 1996, vol. 6, No. 1, Mar. 1996. |
Written Opinion of the International Searching Authority issued by the European Patent Office dated Jul. 17, 2008. |
Number | Date | Country | |
---|---|---|---|
20190180855 A1 | Jun 2019 | US |
Number | Date | Country | |
---|---|---|---|
60902490 | Feb 2007 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15670551 | Aug 2017 | US |
Child | 16186996 | US | |
Parent | 12071486 | Feb 2008 | US |
Child | 15670551 | US |